Identification of β-hydroxybutyrate as a potential biomarker for female papillary thyroid cancer.
Aim: β-Hydroxybutyrate (BHB) was proved to be a differential metabolite of papillary thyroid cancer (PTC) by semiquantitative analysis, while whether BHB could be used as a potential biomarker for female PTC still needed to be validated. Materials & methods: An LC-MS/MS method with surrogate matrix was established to validate serum BHB in specified PTC patients. Conclusion: Serum BHB levels in PTCs were significantly higher than those in HCs. For both serum BHB with a cut-off value of 312.5 ng/ml and serum BHB/creatinine of 33.5 μmol/mmol, a promising prediction rate to distinguish low-grade PTCs from HCs with satisfactory sensitivity and specificity was achieved, indicating that serum BHB might be proved as a useful biomarker for low-grade female PTC.